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Human very small embryonic-like (hVSEL) cells are a resident population of multipotent stem cells in the bone
marrow involved in the turnover and regeneration of tissues. The levels of VSEL cells in blood are greatly
increased in response to injury, and they have been shown to repair injured tissues. Adult hVSEL cells, SSEA-
4 +/CD133 +/CXCR4 +/Lin -/CD45 - , express the pluripotency markers (Oct-4 and Nanog) and may be able to
differentiate into cells from all 3 germ lineages. hVSEL cells isolated from blood by apheresis following gran-
ulocyte–colony-stimulating factor mobilization were fractionated and enriched by elutriation and fluorescence
activated cell sorting. Collagen sponge scaffolds containing 2,000–30,000 hVSEL cells were implanted into cranial
defects generated in SCID mice. Analysis by microcomputed tomography showed that a cell population con-
taining VSEL cells produced mineralized tissue within the cranial defects compared with controls at 3 months.
Histologic studies showed significant bone formation and cellular organization within the defects compared
with cellular or scaffold controls alone. Antibodies to human leukocyte antigens demonstrated that the newly
generated tissues were of human origin. Moreover, human osteocalcin was identified circulating in the pe-
ripheral blood. There was evidence that some level of hVSEL cells migrated away from the defect site, using
quantitative real-time polymerase chain reaction to detect for human-specific Alu sequences. This study dem-
onstrates that hVSEL cells are able to generate human bone tissue in a mouse model of skeletal repair. These
studies lay the foundation for future cell-based regenerative therapies for osseous and connective tissue disor-
ders, including trauma and degenerative conditions, such as osteoporosis, fracture repair, and neoplastic repair.
Introduction
Bone loss due to fractures and disease is a seriousmedical condition that affects millions of individuals
worldwide. While major efforts have been made to understand
mechanisms of healing of skeletal structures and to develop
therapeutics to treat overall bone loss due to the many meta-
bolic bone diseases, information on bone remodeling is scarce
in the human craniofacial skeleton. One approach to repair and
regenerate bone loss is through the use of stem-cell-based
therapy. Bone marrow (BM)–derived mesenchymal stem cells
(MSCs) are capable of differentiating into osteoblasts and other
cells of mesenchymal lineage. They can be directed to do so in
vitro and when implanted in bone can also facilitate bone
formation. In fact, several studies have shown that MSCs can
be employed to regenerate craniofacial bone in animal studies,
supporting the potential of stem-cell-based therapy for bone
repair [1–5]. However, there are potential limitations to the use
of autologous MSCs in bone repair in humans because
most preparatory protocols require the extensive expansion of
MSC populations in vitro using animal-derived or recombi-
nant growth factors as well as modulators of transcription and
cell survival.
In previous reports we described an in vivo assay to
identify cells with stem-cell-like activities [6,7]. Murine
marrow cells with stem-cell-like activities were found to be
present in a low density fraction that was resistant to 5-
fluorouracil in vivo [7]. Further characterization of these cells
identified a fluorescence activated cell sorting profile that
identified a very small cell type that expressed the Sca-1
antigen but did not express the pan-hematopoietic CD45
antigen or other hematopoietic lineage markers (Lin - ). This
Lin -Sca-1 +CD45 - population has previously been described
as having embryonic-like features and are therefore referred
to as very small embryonic-like or VSEL cells [8–11]. Freshly
isolated Lin-Sca-1+CD45- cells, when used in an in vivo
model, demonstrated that as few as 500 cells are able to
generate bone-like tissues [12]. Importantly, when transplanted
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to a BM environment, the cells are able to differentiate into
multiple mesenchymal lineages [6].
In the present report we evaluated the ability of human
VSEL (hVSEL) cells to generate bone structures in vivo. We
demonstrated that hVSEL cells were able to form cortical and
trabecular osseous structures when implanted into cranial
defects in immune-deficient mice. Importantly, the re-
generated bone tissue is of human origin as determined by
immunohistochemistry for human-specific leukocyte anti-
gens (HLAs). These data demonstrate that hVSEL cells form
bone in a preclinical model and therefore represent a novel




hVSEL cells were collected and processed under an IRB
approved protocol at the NeoStem Laboratory in Cambridge,
Massachusetts. Healthy Caucasian men (age 23–27) were
recruited as VSEL cell donors and screened for known dis-
eases, use of drugs and tobacco, and obesity. Two days prior
to apheresis, each donor received daily subcutaneous injec-
tions of granulocyte–colony-stimulating factor [G-CSF
(Neupogen; Amgen, Inc.)] (480mg/day) to facilitate mobi-
lization of VSEL cells from the BM into the peripheral blood
stream. Apheresis was conducted by a certified staff techni-
cian over the course of 2 to 3 h. All the solutions, tubing, and
needles were sterile, used only one time and then discarded
after each donation. Subsequently, the hVSEL cells were
enriched by Elutriation (CaridianBCT), followed by CD34/
CD133 Microbeads (Miltenyi Biotec) positive selection, and
then viable Lin -CD45 -CD34+CD133 + VSEL cells were flow
sorted using Moflo XDP high-speed cell sorter (Beckman
Coulter). Highly purified VSEL cells from 3 donors were
frozen in phosphate-buffered saline–5% human serum al-
bumin and 5% dimethyl sulfoxide (Sigma Chemical Corp.)
and shipped by overnight courier to the University of Mi-
chigan without any demographic information. Upon thaw-
ing, VSEL cells were counted using Trypan Blue exclusion
(Sigma). Typically fewer than 100,000 VSEL cells were iso-
lated and therefore to accommodate all the groups used in
the study 2,000 cells were set as standard cell dose. In one
case, > 3,000,000 VSEL cells were isolated which afforded the
opportunity to increase the cell numbers used.
Animal procedures
Five-week-old female SCID mice (CB.17. SCID; Taconic)
were divided randomly into 5 groups consisting of 10–13
animals per group, except for the 500,000 cell dose in which
n = 5 animals were used. The animals were anesthetized by
continuous isoflurane inhalation, hair was removed by
shaving, and a linear scalp incision was made from the nasal
bone to the occiput and full-thickness flaps were elevated. A
trephine was used to create a 3-mm craniotomy defect cen-
tered in each of the parietal bones with constant irrigation
with Hanks’ balanced salt solution [13]. The calvarial disks
were removed with care to avoid injury of the underlying
dura and brain tissues. After hemostasis was established
(light pressure applied with saline-soaked surgical guaze),
scaffolds (Gelfoam; Pharmacia & Upjohn) previously loa-
ded with either vehicle or hVSEL cells were placed into the
defects so that the scaffolds filled the entire defect. The in-
cisions were closed with 4-0 chromic gut suture (Ethicon/
Johnson & Johnson), and the mice were recovered from an-
esthesia on a heating pad. All mice were sacrificed 16 weeks
after the implantation. This time frame was selected to en-
sure that early healing and early remodeling would have
taken place. At sacrifice, intracardiac puncture and aspira-
tion was performed under anesthesia to collect serum. All
procedures were approved by the University Committee on
the Use and Care of Animals, and Biologic Safety Board in
compliance with State and Federal laws.
Bone marrow stromal cells
BM was isolated by flushing the femurs, tibia, and humeri
of C57BL/6 mice ( Jackson Laboratory) with DMEM +heat
inactivated 10% fetal bovine serum (FBS) (Invitrogen). Plastic
adherence at 37C was performed in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS and
penicillin/streptomycin (Life Technologies). Following
overnight adherence, the nonadherent cells were removed
and fresh medium was replaced. The cultures were ex-
panded by trypsinization twice over the course of 3 weeks
generating first and second passage cells (P1 or P2). Bone
marrow stromal cells (BMSCs) from P1 or P2 at 80%–90%
confluence were transduced with AdCMVBMP-7 ex vivo
24 h prior to transplantation at a multiplicity of infection of
500. The AdCMVBMP-7 was constructed by Cre-lox recom-
bination as previously described and generated by Vector
Core at the University of Michigan [14].
Cell transplantation
Five groups of mice were established to evaluate the
ability of hVSEL cells to regenerate the cranial defects.
The first group served as a negative control in which only the
vehicle and Gelfoam were placed into the defect. The second
group consisted of P1 or P2 murine BMSCs infected with an
AdCMVBMP-7 designed to express huBMP-7 to serve as a
positive control [14]. Our test groups consisted of 2,000,
10,000, 30,000, and 500,000 VSEL cells in Gelfoam isolated
from 3 different human donors.18 The cell doses were de-
rived at by estimating the frequency of these marrow human
MSCs reported to be present in BM (ranging from 1/10,000
to 1/100,000 BM mononuclear cells) [15–19] and observa-
tions that * 2· 106 human marrow adherent cells are re-
quired to heal a 5-mm cranial defect in mice [1]. The
incorporation of a 2,000 VSEL cell dose was to ensure our
ability to observe a VSEL cell response assuming that only
10% of the transplanted cells were able to participate in
wound repair. BMSCs transduced with AdCMVBMP-7
(2,000 cells/implant) were used as controls. Negative con-
trols included the scaffold alone.
Microcomputed tomography
Calvariae were harvested and immediately fixed in 10%
neutral buffered formalin for 48 h. The bone specimens were
then scanned at 8.93 mm voxel resolution on an EVS Corp.,
micro-CT scanner, with a total of 667 slices per scan. GEMS
MicroView software was used to make 3-D reconstructions
from the data set. Each defect was individually assessed for
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the region of interest and bone analysis was conducted with
a fixed threshold (600) used to extract the mineralized bone
phase; bone volume fraction, bone mineral density, and
trabecular number were calculated.
Histologic examination
After microcomputed tomography (mCT) analysis, the
bones were decalcified in 10% EDTA (pH 7.4) for 10 days and
embedded in paraffin. Longitudinal sections of the calvariae
were cut and stained with hematoxylin and eosin (H&E) or
using Masson’s trichrome staining and analyzed by light mi-
croscopy. In some cases, the slides were stained with an anti-
body to human HLA antigens [Anti-HLA-ABC antibody
(BioLegend)] or an IgG control (Sigma-Aldrich) in conjunction
with an HRPAEC staining system kit following the manufac-
ture’s protocols (R&D Systems) to identify the human cells.
Serum osteocalcin levels
Human osteocalcin levels were determined using a sand-
wich Mid-Tact Osteocalcin EIA (Biomedical Technologies) and
using human recombinant osteocalcin as a standard (Biome-
dical Technologies). This sandwich EIA is highly specific for
both intact human osteocalcin and the major (1–43) fragment.
To normalize the osteocalcin levels in the serum, total protein
was determined using the RC-DC Protein Assay Kit (BioRad
Laboratories) against a bovine serum albumin standard. Hu-
man serum was purchased from Sigma as a positive control.
Real-time polymerase chain reaction
evaluation for hVSEL cells
DNA isolation kits were used to prepare genomic DNA
from the designated tissues [DNeasy Blood and Tissue Kit
(Cat. No. 69506); Qiagen, Inc.]. All sample concentrations
were standardized in each reaction to exclude false-positive
results. Real-time polymerase chain reactions were per-
formed using 15.0 mL of TaqMan PCR Master Mix (Applied
Biosystems) with 100 nM of the human Alu TaqMan probes
[(F: 5¢-CAT GGT GAA ACC CCG TCT CTA-3¢, R: 5¢-GCC
TCA GCC TCC CGA GTA G-3¢; TaqMan probe: 5¢-FAM-
ATT AGC CGG GCG TGG TGG CG-TAMRA-3¢); Applied
Biosystems] [20,21] and 1mg of the isolated tissue DNA in a
total volume of 30mL. The thermal conditions were 50C for
2 min and 95C for 10 min followed by 40 cycles of 95C for
15 s and 60C for 1 min. The level of expression was detected
as an increase in fluorescence using a sequence detection
system (ABI PRISM 7700; Applied Biosystems). The DNA
levels were expressed as relative copies (% control) normal-
ized against murine b-actin (Cat. No. 4331182; Applied Bio-
systems), and a standard curve constructed from serial
dilutions of a purified Luc/Alu cDNA fragment was cloned by
classic polymerase chain reaction (PCR). Numerical data were
determined against a standard curve established using mouse
BM containing log-fold dilutions of hVSEL cells. Positive
controls used DNA isolated from a human prostate cancer cell
line (PC3). Negative controls included tissues isolated from
animals not injected with hVESL cells.
Statistical analyses
Numerical data are expressed as mean– standard devia-
tion. Statistical analysis was performed by Kruskal–Wallis
one-way analysis of variance using the GraphPad Instat
statistical program (GraphPad Software). Specific differences
were measured by Mann–Whitney U test. The level of sig-
nificance was set at P < 0.05.
Results
Evaluation of bone formation by lCT
hVSEL cells were evaluated for their ability to form bone
in murine calvarial defects. VSEL cells were isolated fol-
lowing G-CSF mobilization of normal healthy donors and
placed into 3-mm-diameter calvarial defects generated in the
left parietal bones of SCID mice. Transplanted cells (ranging
from 2,000 to 500,000 cells) were delivered to the defects in
3 · 3 mm GelFoam collagen sponges. Negative cellular con-
trols consisted of the sponge alone. Positive controls incor-
porated murine BMSCs engineered to overexpress human
BMP7. After 3 months all the specimens were evaluated by
mCT. The data demonstrate that animals implanted with
carrier alone did not generate any bone compared with the
mineralized tissue formed in the positive control (Fig. 1).
FIG. 1. Human very small embryonic-like (hVSEL) cells form bone in immune-deficient mice. Microcomputed tomography
images of the calvarial specimens show several representatives of calvarial defects following VSEL cell implantation. Bone
marrow stromal cells (BMSCs) from P1 or P2 at 80%–90% confluence were transduced with AdCMVBMP-7 ex vivo 24 h prior
to transplantation and implanted at 2,000 cells/defect served as a positive control. The data show the lack of mineralized
tissue present within the defects within the negative control (collagen carrier alone). Each of the VSEL-cell-implanted defects
generated mineralized tissues.
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Implantation of 2,000–500,000 VSEL cells from the 3 donors
all stimulated bone formation (Fig. 1). Examination of the
mineralization demonstrated incomplete closure of all of the
defects. However, robust bone formation was observed in
samples generated from the 2,000 and 10,000 cells/implant
groups. Interestingly, bone formed in animals treated with
30,000 cells/implant did not produce significantly more os-
seous tissue than those treated with 2,000 cells/implant and
the 500,000 cells/implant produced greater boney structures
than did the 30,000 and 2,000 cells/implant groups.
Using the GEMS MicroView software, each sample was
examined for mineral content. The efficacy of cells to pro-
duce mineralized matrix was not proportional to the number
of cells transplanted (Fig. 2A). For example, defects im-
planted with 2,000 hVSEL cells produced more mineralized
tissue than those implanted with 10,000 or 30,000 cells. In-
terestingly, implants with 30,000 hVSEL cells produced the
lowest amount of mineralized tissue. The most mineralized
tissue that was formed was when 500,000 VSEL cells were
implanted within the calvarial defects; however, the amount
of tissue formation was not statistically different from the
tissue generated by 2,000 VSEL cells.
As previously described, hVSEL cell isolation was col-
lected from 3 separate donors. Total VSEL cells isolated and
generated were 3,120,000, 19,000, and 11,000 for donors 1, 2,
and 3, respectively. To assess any differences in efficacy in
bone formation between donors, implants from individual
donors were evaluated at the same cell dose. When bone
generated by 2,000 hVSEL cells/implant was compared with
donors 1 and 3, results showed that these groups per-
formed equivalently, but both generated more mineralized
tissue than donor 2 (Fig. 2B). Yet donor 3 generated more
hVSEL cells than the other 2 donors, suggesting that po-
tential individual differences in hVSEL cell function are
possible.
Evaluation of bone formation by histological analysis
After decalcification, serial sections were generated
through each defect in preparation for histologic evaluation.
Implanted material demonstrated a high degree of tissue
integration, with few, if any, neutrophils or macrophages
observed within newly formed tissue. In the control group,
the collagen carrier matrix persisted and no osteoid or ma-
ture lamellar bone could be observed by H&E or Masson’s
trichrome staining (Fig. 3). In experimental groups implanted
with 2,000 hVSEL cells, woven bone containing marrow
spaces was observed within the calvarial defect (Fig. 3).
Here, the carrier matrix was largely resorbed from the defect
site with few remaining particles embedded within fibrous
connective tissue surrounding the lamellar bone. The bone
generated was comprised predominantly of woven bone
(Fig. 3).
Demonstration that hVSEL cells formed bone in vivo
To validate that the bone formed was generated by the
implanted human cells, 2 independent methods were eval-
uated. First, the sections were stained with a pan-HLA an-
tibody. Mice implanted with vehicle only did not
demonstrate any cross-reactivity for human HLA (Fig. 4A).
Mice implanted with hVSEL cells demonstrated significant
human HLA staining specifically on cells lining the bone
surface and in other cells in the marrow (Fig. 4B–D). To-
gether, these results show that injected hVSEL cells localize
to mouse BM spaces adjacent to bony trabeculae and dem-
onstrate that VSEL cells are likely to be active participants in
bone formation.
To prove that the hVSEL cells generated bone, serum from
the animals collected at the time of sacrifice (3 months) was
evaluated for the presence of human-specific osteocalcin.
Animals that did not receive any hVSEL cells in their im-
plants did not demonstrate any human osteocalcin in the
serum (Fig. 5). Animals that were implanted with hVSEL
cells did have circulating human osteocalcin present within
their serum (Fig. 5). The levels of osteocalcin roughly corre-
sponded to the amount of bone formation with animals
receiving 500,000 cells/implant having the highest concen-
tration of osteocalcin present in the serum, and animals
implanted with fewer hVSEL cells demonstrating less os-
teocalcin in the blood (Fig. 5).
FIG. 2. Mineral content generated by hVSEL cells in im-
mune-deficient mice. (A) hVSEL cells were implanted into
n = 10 calvarial defects over a dose range of 2,000–30,000
cells/defect and n = 5 for 500,000 cells/defect. Groups con-
sisting of 30,000 and 500,000 VSEL cells/defect were isolated
from a single donor. At 3 months the tissue mineral content
values within each defect were averaged for the animal
groups. Positive controls included murine BMSCs expressing
human BMP7; negative controls consisted of only the colla-
gen carrier alone. (B) Averages of tissue mineral content
formed within the calvarial defect by 2,000 hVSEL cells by
donor (*P < 0.05).
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FIG. 3. Histologic evaluation of tissues generated by hVSEL cells within calvarial defects. Representative slides were stained
with hematoxylin and eosin (top row) and Masson’s trichrome (bottom row) in which collagen and bone appear blue. Positive
controls included murine BMSCs expressing BMP7 (not shown); negative controls (neg. control) consisted of only the
collagen carrier alone. Histology presented at 20 · (insets) and 40· magnifications. Note the persistence of the collagen
carrier matrix in the neg. control group as well as the absence of an inflammatory cell infiltrate. The 2,000 hVSEL cell groups
demonstrate lamellar bone containing marrow spaces (arrows). Scale bar = 100mm.
FIG. 4. Tissues generated by hVSEL cells are derived from human cells. Tissues formed by hVSEL cells within calvarial
defects were stained with a fluorescent human-specific pan-human leukocyte antigen (HLA) (red) and merged with images of
antinuclear stain (DAPI) and differential interference contrast (DIC) images. (A) Negative control is a longitudinal section of
vessel in mice implanted with vehicle only demonstrating lack of human HLA staining. (B–D) Longitudinal section of a
vessel in mice injected with hVSEL cells demonstrating cytoplasmic human HLA staining. Histologic images presented at
40 · . Scale bar = 100mm.
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Migration of hVSEL cells from the bone defects
Migration of hVSEL cells from the implant site into the
periphery was assessed using quantitative real-time PCR for
human-specific Alu sequences. The presence of human DNA
was evaluated from representative tissue samples from the
spleen, femur, right lobe of the liver, and whole blood. An-
imals not implanted with human cells and animals im-
planted with murine BM served as a negative control. A
human prostate cancer cell line (PC-3) mixed (1:1,000) with
murine BM served as a positive control. Human-specific Alu
expression was identified at low levels in the blood of the
recipient animals that were implanted with hVSEL cells (Fig.
6). No evidence of human DNA was seen in the spleen, fe-
mur, or liver of the animals implanted with hVSEL cells,
suggesting that the level of VSEL cells that migrated out of
the defect was relatively low (Fig. 6).
Discussion
Bone is a specialized and dynamic tissue that undergoes
continuous remodeling throughout life [22]. Osteoblasts, de-
rived from stem cells of mesenchymal origin, are responsible
for the synthesis of the bone matrix that ultimately becomes
mineralized. Their origin appears to be derived from a pop-
ulation of stem cells frequently described as MSCs. Numerous
models have demonstrated that MSCs are capable of limited
self-renewal and are able to undergo differentiation into
multiple lineages, including bone, adipocytes, cartilage, and
hematopoiesis-supporting cells [23]. This capacity to form
new osseous tissues has many clinical applications, including
treatment for patients with boney defects, poor bone mass, or
deficient fracture repair. However, limitations in our ability to
collect and expand MSCs along with difficulties in activating
and driving MSCs in situ with current therapeutic modalities
limit the local or systemic treatment of many skeletal condi-
tions. These modalities include the use of human recombinant
parathyroid hormone (PTH) treatments, calcium and vitamin
D to stimulate osteoblastic bone formation, or bisphosphonate
therapies to inhibit osteoclastic activities.
Recent work in regenerative medicine has demonstrated
that marrow and other tissues contain a population of non-
hematopoietic stem cells with many properties of pluripotent
stem cells [24]. First described by Ratajczak and coworkers,
these VSEL cells (< 8mm) appear to have the ability to gen-
erate all 3 germ layer cellular populations under experimental
conditions [8,22–37]. They are found in BM [8,24,26,27,29],
cord blood [25,38], and adult peripheral blood [30] and other
adult organs [31,39,40]. Murine VSEL cells express SSEA-1+ ,
Oct-4+ , and Sca-1+ but do not express hematopoietic lineage
markers (lin- and CD45- ). hVSEL cells are SSEA-4+/Oct-4+/
CD34+/lin+/CD45+ . Morphologically, VSEL cells appear to
be mostly comprised of a relatively large nucleus with scant
cytoplasm, and express early embryonic transcription factors,
including Oct-4, Nanog, and the chemokine receptor CXCR4.
Due to their expression of CXCR4, they are highly sensitive to
stromal derived factor-1 (SDF-1 or CXCL12), which is likely to
be a critical feature in their ability to be mobilized and mi-
gration in response to tissue injury. VSEL cells are also highly
sensitive to G-CSF, which can induce their mobilization from
BM into the blood and other organs and tissues.
FIG. 5. Human osteocalcin
present in murine serum. Cir-
culating levels of intact human
osteocalcin present in the se-
rum (3 months) of animals im-
planted with no human cells
(negative control), carrier alone
(sponge alone), or human se-
rum (positive control), murine
BMSCs expressing human
BMP, or 2,000–500,000 hVSEL
cells/defect. Osteocalcin levels
are presented as the mean and
standard deviation of all ani-
mals/implant group normal-
ized against total serum
protein. *P < 0.05 compared
with negative control.
FIG. 6. Human cells are found in the blood of experimental
animals. Quantitative real-time polymerase chain reaction
for human-specific Alu was used to determine the presence
of human cells within select murine tissues (spleen, femur,
right lobe of the liver, and whole blood). Pure mouse bone
marrow served as a negative control and human prostate
cancer cell line (PC3) served as a positive control. Human
DNA was not observed in the spleen, femur, or liver of any
of the animals implanted with 2,000 hVSEL cells. Human-
specific Alu was detected in the peripheral blood of the an-
imals. *P < 0.05 compared with negative control.
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The results of our studies establish that hVSEL cells can be
isolated from human peripheral blood and are capable of
osseous regeneration in a cranial defect in immune-deficient
mice. However, the ability of these cells to completely re-
constitute a large skeletal defect was limited. As demon-
strated by HLA staining, the bone formed was derived from
the human cells and did not specifically represent cells in-
duced from the host animal that were recruited into the os-
seous site. Moreover, enzyme-linked immunosorbent assay
specific for human osteocalcin, a noncollagenous protein often
used as a biochemical marker for bone formation, was found
in the serum of the animals. Secreted specifically by the os-
teoblasts into the bone matrix, osteocalcin is believed to play a
pivotal role in the mineralization of the bone matrix. Osteo-
calcin is known to circulate in the blood as the intact protein
as well as the major N-terminal fragment [41]. However, only
a small fraction of the total osteocalcin is known to be released
into the circulation, with most being deposited within the
bone matrix [42]. Thus, the level of osteocalcin in the circu-
lation, while indicative of tissue turnover, may not be truly
reflective of bone formation in this model.
A perplexing aspect of the findings is that the results did
not necessarily correlate with the number of cells placed in
the defect. We expected to observe greater osseous regener-
ation when a greater number of hVSEL cells were placed per
defect. We did observe that placing 500,000 cells/implant
produced the most bone, but defects grafted with 2,000 cells
performed better than 10,000 and 30,000 cells. It is not clear
why the tissue response did not mirror those in other re-
generative studies. One possible explanation is that stem
cell–to–stem cell communication is important under the ex-
perimental conditions. This concept is not unprecedented in
the stem cell field where one daughter of a stem cell remains
as a stem cell while the other matures and differentiates
taking on a tissue-specific phenotype [43,44]. Thus, a po-
tential decrease in regenerative capacity may have reduced
the osteogenic production of 10,000 versus 30,000 cells, but
may be overcome when cell concentrations are either much
higher or when other exogenous factors participate in local
tissue construction. Along these lines there are several in-
stances where mature cell progeny output is facilitated by
lower inoculum densities, including cells derived from he-
matopoietic and mesenchymal lineages [45].
Throughout our studies hVSEL cells were isolated from a
number of different donors. Not unexpectedly, we observed
significant differences in osseous tissue formation among
donors even with equivalent cell dosing. From a therapeutic
standpoint this suggests that there are likely to be inherent
differences in the abilities of VSEL cells isolated from dif-
ferent individuals, or a spectrum of activities in the VSEL cell
phenotype caused by the isolation and purification methods.
This is best illustrated by the observation that equivalent
numbers of frozen and thawed VSEL cells did not function as
well in generating bone in our studies, as did VSEL cells that
had not been frozen (unpublished observations). Yet the
basis for these observations remains unclear. We did explore
in this context a number of methods to improve tissue re-
generation, including the delivery of exogenous PTH and
erythropoietin; however, no significant differences were no-
ted (not shown). At present, there are a multitude of opera-
tional factors that may have bearing on our results. For
example, GelFoam matrix was used as a scaffold in our
studies; it may not be ideal for mineralized tissue formation in
conjunction with hVSEL cells. hVSELs may require a miner-
alized matrix for proper osseous formation to occur. In addi-
tion, we did not evaluate the ability of this material to maintain
sufficient space for tissue regeneration. Thus, while the Gel-
Foam in the formulation we used is pliable and compressible,
it may have collapsed within the defect limiting the extent of
the tissue that could have been generated. Alternatively, the
carrier may not have been sufficient to hold hVSEL cells in
the wound site such that they were able to migrate out of the
defect and therefore not contribute to regeneration. This re-
mains a distinct possibility since we were able to identify hu-
man Alu signatures in the peripheral blood of the animals.
Equally important to the results is the concept that the
timing of our VSEL cell collections or animal studies may not
have been optimized for calvarial regeneration. hVSEL cells
may require a longer experimental period for differentiation
into osteogenic cells and for the production of sufficient os-
seous tissue to complete the closure of the defect. There are
numerous examples whereby differences in stem cell char-
acteristics are known to contribute to short- and long-term
reconstitution [43,44]. It has been proposed that VSEL cells
are a quiescent population that reside within the BM [31],
and after being mobilized into peripheral blood, they par-
ticipate in the turnover of other tissue-specific stem cells that
are located in peripheral niches, and play a role in tissue
organ regeneration [24,29]. Thus, while VSEL cell numbers
are normally at very low levels in blood, the ability to mo-
bilize them into the blood is particularly attractive from the
standpoint of developing a therapeutic product. This has
been shown in clinical studies where VSEL cells were mo-
bilized into peripheral blood following acute myocardial
infarction [46] and stroke [47]. The mobilization appears to
be a protective reaction of the body to repair heart tissue in
response to injury. In fact, VSEL cells have been shown to
repair cardiac tissue in an animal model of acute myocardial
infarction [36]. Other studies show that VSEL cells can be
used to treat retinal injuries [48] and diabetes [37]. Most
importantly, procedures have been developed to isolate
VSEL cells from cord blood and as in this study, hVSEL cells
were mobilized into peripheral blood by G-CSF stimulation
[32]. However, inherent in the mobilization process, there
may be deleterious activities on the ability of VSEL cells to
participate in osseous function in our model. While we did
not specifically examine osteoclastic activities, G-CSF is well
known to activate the formation of osteoclasts and to inhibit
osteoblastic function. Thus, while exogenous G-CSF was not
administered to the mice during the studies, the effects of
mobilization alone on VSEL cells require closer examination.
As a prerequisite to clinical trials, it is important to de-
termine whether the hVSEL cells were able to migrate away
from the calvarial defect site. Upon end-point of the experi-
ments, the spleen, femur, right lobe of the liver, and whole
blood were removed to isolate genomic DNA. Using quan-
titative real-time PCR for human-specific Alu sequences, we
were able to detect the presence of human-specific cell lines.
We observed low levels of human-specific Alu expression in
the blood of the recipient animals; however, no Alu expres-
sion was identified in the peripheral tissues examined. A
possible explanation is that hVSEL cells were present in the
tissues but fell below the level of detection of our assays,
remaining as a reserve stem cell compartment [46,49].
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Recently, it was demonstrated that culture-expanded VSEL
cells have the capacity to generate cells in the hematopoietic
lineages [50]. While we do not have specific data that address
whether the results of the blood PCR were due to the hVSEL
cells becoming hematopoietic cells, it remains a possibility,
although we would have expected to see similar results in
the spleens of the animals.
In conclusion, this study demonstrates that hVSEL cells
can generate human bone in a mouse model of skeletal re-
pair. These studies lay the foundations for future cell-based
regenerative therapies for osseous and connective tissue
disorders, including trauma and degenerative conditions,
such as osteoporosis and fracture repair. While much needs
to be learned pertaining to cell delivery, timing, matrices,
and differences between individuals, the ability of VSEL cells
to generate human bone could have numerous clinical ap-
plications, especially since alternative approaches to induce
new bone formation have associated limitations. Thus, the
ability to harvest and deliver these cells as a therapeutic
agent has great potential to enhance bone formation in states
of poor bone growth or deficient fracture repair.
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